BioPharma Resources

Drug Trial Radar · NCT05119686

Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients

A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 Versus Placebo in Gout Patients

Last checked: Nov 19, 2026Latest source record: May 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Nov 16, 2021

Primary completion

Nov 17, 2022

Study completion Nov 17, 2022

Sponsor

Lead sponsor
Arthrosi TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 weeks.

Conditions

  • Gout
  • Arthritis, Gouty
  • Hyperuricemia
  • Gout Chronic

Interventions

  • AR882 Dose 1Drug

    Solid Oral Capsule

  • AR882 Dose 2Drug

    Solid Oral Capsule

  • PlaceboDrug

    Matching Solid Oral Capsule Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serum urate (uric acid) (sUA) level < 6 mg/dL following 6 weeks of dosingTime frame: 6 weeks

Locations

23 sites in 3 countries. Site status is shown where the registry gives one.

  • Arthrosi Investigative Site

    Gilbert, Arizona

  • Arthrosi Investigative Site

    Sun City, Arizona

  • Arthrosi Investigative Site

    Tucson, Arizona

  • Arthrosi Investigative Site

    Miami, Florida

  • Arthrosi Investigative Site

    Miami Lakes, Florida

  • Arthrosi Investigative Site

    Tampa, Florida

  • Arthrosi Investigative Site

    Honolulu, Hawaii

  • Arthrosi Investigative Site

    Overland Park, Kansas

  • Arthrosi Investigative Site

    Cleveland, Ohio

  • Arthrosi Investigative Site

    Cleveland, Ohio

  • Arthrosi Investigative Site

    Duncansville, Pennsylvania

  • Arthrosi Investigative Site

    Dallas, Texas

  • Arthrosi Investigative Site

    Houston, Texas

  • Arthrosi Investigative Site

    Tomball, Texas

  • Arthrosi Investigative Site

    West Jordan, Utah

  • Arthrosi Investigative Site

    Glendale, Wisconsin

  • Arthrosi Investigative Site

    Melbourne, Camberwell, Australia

  • Arthrosi investigative Site

    Botany, New South Wales, Australia

  • Arthrosi Investigative Site

    Taichung, Taiwan

  • Arthrosi Investigative Site - 301

    Taipei, Taiwan

  • Arthrosi Investigative Site - 304

    Taipei, Taiwan

  • Arthrosi Investigative Site

    Taipei, Taiwan

  • Arthrosi Investigative Site

    Taoyuan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.